Shares of RPC, Inc. (NYSE:RES) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 2.03% to close at $21.66. RPC Inc. (RES) declared a loss of $21.1 million in its fourth quarter. On a per-share basis, the Atlanta-based company said it had a loss of 10 cents. The results topped Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share. The oil and gas services company posted revenue of $221 million in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $204.3 million. For the year, the company declared that its loss widened to $141.2 million, or 66 cents per share. Revenue was declared as $729 million. Moving forward to saw long-term intention, the experts calculate Return on Investment of -10.80%. The stock is going forward its fifty-two week low with 116.37% and lagging behind from its 52-week high price with -2.78%. RES last month stock price volatility remained 2.32%.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) [Trend Analysis] retains strong position in active trade, as shares scoring 2.42% to $3.38 in a active trade session, while looking at the shares volume, around 362367 shares have changed hands in this session. Orexigen Therapeutics, Inc. (OREX) reported that LaboratoriosFarmacéuticosRovi, S.A. (ROVI) has launched Mysimba in Spain. Mysimba is authorized by the European Medicines Agency for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obese), or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
ROVI will market Mysimba as part of their diversified pharmaceutical portfolio under the terms of our distributorship contract signed in August 2016. “The launch of Mysimba in Spain is an important milestone in our partnership with ROVI, a company who shares our objective to improve the quality of life for patients who are overweight or struggle with obesity,” said Mike Narachi, President and Chief Executive Officer of Orexigen. “With this launch, Mysimba is now accessible for patients in six countries in Europe. We expect to continue to grow availability of this important therapeutic option for weight management with launches in ten additional European countries in 2017.”
The firm has institutional ownership of 57.50%, while insider ownership included 0.10%. OREX attains analyst recommendation of 3.30 with week’s performance of 6.96%. Investors looking further ahead will note that the Price to next year’s EPS is 46.80%.